Johnson & Johnson Targets Procedure Growth With Bladder Cancer And Vision Advances [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Johnson & Johnson (NYSE:JNJ) reported first in human Phase 1 results for an extended release erdafitinib delivery system in non muscle invasive bladder cancer, showing promising complete and durable responses with a favorable safety profile. The company also received FDA approval for its TECNIS PureSee intraocular lens, an extended depth of focus option for cataract surgery that targets presbyopia and visual clarity without contrast sensitivity loss warnings. Johnson & Johnson, through its pharmaceuticals and MedTech segments, continues to develop treatments and devices for large, long term health needs such as cancer and age related vision loss. These two updates offer a view into how the group is working across both drug delivery and medical devices in areas where patients often have limited options. For investors watching NYSE:JNJ, these milestones highlight pipeline progress that exists alongside the company's established product portfolio. The real test will come from larg
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout [Yahoo! Finance]Yahoo! Finance
- Martin Cobb's Top Picks for March 24, 2026 [BNN Bloomberg (Canada)]BNN Bloomberg
- Golfweek Masters Survey: Favorite picture from Augusta National [USA TODAY]USA TODAY
- Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi [Seeking Alpha]Seeking Alpha
- Johnson & Johnson (JNJ) Advances Bladder Cancer Treatment with 89% Response Rate [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 3/18/26 - Form 13F-HR/A
- 3/18/26 - Form 13F-HR/A
- 3/12/26 - Form 4
- JNJ's page on the SEC website